Mice treated later (when lesions were millimeter scale in size) experienced significant tumor growth retardation and survival benefit in both monotherapy and tandem regimes of 177Lu- and 225Ac-PSMA therapy. This evidence concerns the gene FOLH1 and neoplasm.